GGTA1 KO Thymokidney

Phase 1/2Recruiting

0 views this week 0 watching💤 Quiet

Interest: 36/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

ESRD (End-Stage Renal Disease)

Conditions

ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation

Trial Timeline

Mar 1, 2026 → Mar 1, 2076

NCT ID

NCT07224763

About GGTA1 KO Thymokidney

GGTA1 KO Thymokidney is a phase 1/2 stage product being developed by United Therapeutics for ESRD (End-Stage Renal Disease). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07224763. Target conditions include ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation.

What happened to similar drugs?

4 of 8 similar drugs in ESRD (End-Stage Renal Disease) were approved

Approved (4) Terminated (0) Active (4)

✅DoravirineMerckApproved

✅Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNINovartisApproved

✅Mycophenolic Acid (Myfortic)NovartisApproved

✅Physioneal + Dianeal + Extraneal + NutrinealBaxterApproved

🔄RoxadustatAstraZenecaPhase 3

🔄Dianeal + Physioneal + Extraneal + NutrinealBaxterPhase 3

🔄Dianeal + Dianeal, Extraneal, NutrinealBaxterPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07224763	Phase 1/2	Recruiting	Mar 1, 2026	Mar 1, 2076	ESRD (End-Stage Renal Disease)

Competing Products

17 competing products in ESRD (End-Stage Renal Disease)

See all competitors

Product	Company	Stage	Hype Score
Roxadustat	AstraZeneca	Phase 3	40
Doravirine	Merck	Approved	43
MK-2060 + Placebo	Merck	Phase 1	29
Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI	Novartis	Approved	43
Mycophenolic Acid (Myfortic)	Novartis	Approved	43
Avacopan	Amgen	Phase 1	29
[¹⁴C]Etelcalcetide	Amgen	Phase 1	29
apixaban	Bristol Myers Squibb	Phase 2	35
ISIS 416858 + Placebo	Bayer	Phase 2	32
ISIS 416858 + Placebo	Bayer	Phase 2	32
10 GE Xenokidney	United Therapeutics	Phase 1/2	36
Dianeal + Physioneal + Extraneal + Nutrineal	Baxter	Phase 3	37
Physioneal + Dianeal + Extraneal + Nutrineal	Baxter	Approved	40
Dianeal + Dianeal, Extraneal, Nutrineal	Baxter	Phase 3	37
Acellular Tissue Engineered Vessel (ATEV)	Humacyte	Phase 3	37
Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate	Rockwell Medical	Phase 2	25
soluble ferric pyrophosphate (SFP)	Rockwell Medical	Pre-clinical	8